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ABSTRACT 
 
Background:   
InterAtrial Shunt Device (IASD) effects have been described in patients with heart failure (HF) and 
ejection fractions (EFs) ≥40%.  However, baseline characteristics that correlate with greatest 
hemodynamic effects are unknown.  Based on fundamental principles we hypothesized that 
larger pressure gradients between left and right atria would yield greater shunt flow and greater 
hemodynamic effects. 
Methods and Results: 
REDUCE LAP-HF was a multicenter study that investigated IASD safety and performance. 64 
patients with EF≥40% underwent device implantation followed by hemodynamic assessments at 
rest and exercise, including pulmonary capillary wedge pressure (PCWP, surrogate for LA 
pressure) and central venous pressure (CVP).  At 6 months, IASD resulted in an average Qp:Qs of 
1.27 and increased exercise tolerance.  The PCWP-CVP gradient (i.e., the driving pressure for 
shunt flow) decreased at peak exercise from 16.8±6.9 to 11.4±5.5 mmHg, because of increased 
CVP (17.5±5.4 to 20.3±7.9 mmHg, p=0.04) and decreased PCWP (34.1±7.6 to 31.6±8.0 mmHg, 
p=0.025).  Baseline PCWP-CVP gradient during exercise correlated with changes of both PCWP-
CVP and PCWP: Δ(PCWP-CVP)=10.0-0.89·(PCWP-CVP)baseline (r2=0.56) and ΔPCWP=7.54-
0.60·(PCWP-CVP)baseline (p=0.001). Hemodynamics of patients with EF≥50% and those with 
EF<50% responded similarly to IASD. 
Conclusion:  
In HF patients with EF≥40%, IASD significantly reduced PCWP and PCWP–CVP at peak exercise. 
Patients with higher baseline PCWP-CVP gradient had greater reductions in both parameters at 
 4 
follow-up.  Results were sustained through 12 months and were independent of whether EF was 
≥50% or between 40-49%.  Additional studies will help further define the baseline hemodynamic 
predictors of exercise, hemodynamic and clinical efficacy of the IASD.  
Clinical Trial Registration Information:  
NCT01913613  https://clinicaltrials.gov/ct2/show/NCT01913613 
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COMMENTARY 
What is new?  
Interatrial shunts devices (IASD) have been shown to reduce work-normalized pulmonary 
capillary wedge pressure during exercise and are being further investigated as a therapy for 
patients with heart failure and preserved ejection fraction.  However, baseline factors that 
correlate with greatest reductions of PCWP are not known.  We show that the greater the 
difference between pulmonary capillary wedge pressure and central venous pressure (PCWP-
CVP, which is the driving force for flow through the shunt) the greater is the reduction on this 
pressure gradient and the greater the reduction of PCWP at peak exercise.  
What are the clinical implications? 
IASDs have already received Conformité Européene (CE) marking in the European Union and are 
being investigated in the United States.  The current results may help guide clinicians on how to 
evaluate and identify pateints who are most likely to benefit, at least in terms of reductions of 
PCWP.  Additional work is ongoing to determine if reductions of PCWP correlate with clinical 
outcomes. 
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INTRODUCTION 
 
Heart failure (HF) with preserved (HFpEF) accounts for more than half of all cases of HF with a 
prevalence that continues to increase.1  This rising burden has been accompanied by 
disappointing therapeutic results as effective treatment options remain elusive.2  As the 
exploration of alternative management options continues, increasing emphasis has been placed 
on the multitude of HFpEF phenotypes and the wide range of mechanisms that contribute to the 
common spectrum of signs and symptoms.3 
However, regardless of etiology, HFpEF patients all demonstrate excessive increases in left atrial 
pressures in particular during exercise which contributes to effort intolerance and portends a 
worse prognosis.4-8 The understanding of the mechanisms underlying such hemodynamic 
changes has evolved from the now outdated singular concept of diastolic dysfunction to include 
abnormalities in blood volume regulation, increased pericardial restraint and increased 
sensitivity of blood volume distribution to acute neuro-hormonal stimulation during exercise3, 9-
14 and volume loading.6, 15, 16 While many gaps in understanding remain, these studies have led 
to the concept that exercise-induced increase of left atrial pressure is a viable therapeutic target 
for these patients.17-21   
We recently introduced a device-based therapeutic strategy that establishes an interatrial 
communication to allow left-to-right shunting and reduce left atrial pressure.17, 22-27  
Fundamentally, an interatrial shunt will reduce the pressure gradient between the left and right 
atria.  In the setting of heart failure, where left atrial pressure (for which pulmonary capillary 
wedge pressure [PCWP] serves as a surrogate) is elevated above right atrial pressure (and its 
equivalent, central venous pressure [CVP]) a left-to-right shunt is expected and has been 
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demonstrated in our initial clinical studies with the InterAtrial Shunt Device (IASD) including a 
randomized controlled trial.23, 24, 27  However, the baseline characteristics that are associated with 
better hemodynamic and clinical outcomes have not been identified.  Basic principles and 
theories of shunt hemodynamics17 suggest that at a given diameter, shunt flow and the ability to 
reduce left atrial pressure is driven by the pre-existing pressure gradient between atria, which is 
indexed by the difference between PCWP and CVP.  Accordingly, the purpose of the present study 
was to better define changes in PCWP, CVP and their difference in response to exercise and test 
whether the PCWP-CVP gradient correlates with hemodynamic response to IASD.  
 
Methods 
The data and study materials from this study will not be made available to other researchers. 
Study design and subjects 
The REDUCE LAP-HF study was a multicenter, prospective, open-label, single-arm study designed 
to investigate the safety and performance of a transcatheter, transvenous InterAtrial Shunt 
Device (IASD system II, Corvia Medical Inc, Tewksbury, MA, USA). The study design has been 
previously described in detail.22 The data, analytic methods, and study materials will be made 
available to other researchers for purposes of reproducing the results or replicating the 
procedure.  
Patients with heart failure and EF ≥40% (assessed by the clinical site) were eligible for study 
inclusion if they were adults (aged >40 years) with evidence of chronic symptomatic heart failure 
[New York Heart Association (NYHA) functional class II–IV] and increased PCWP (>15 mmHg at 
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rest, or >25 mm Hg during supine bicycle exercise) measured during right heart catheterization 
(RHC).  Patients were excluded for substantial right ventricular dysfunction indexed by elevated 
central venous pressure (CVP > 14 mmHg) or tricuspid annular plane systolic excursion below 14 
mm; as well as for recent (<3 months) myocardial infarction, coronary artery bypass graft, or 
percutaneous coronary intervention; non-ambulatory NYHA IV heart failure; infiltrative or 
obstructive hypertrophic cardiomyopathy; moderate or greater aortic stenosis or mitral 
regurgitation; and severe renal dysfunction. The study protocol was approved by the ethics and 
instutional review committees at each institution and country-specific competent authorities and 
all patients gave informed consent.  The study from which the data are derived is registered 
with ClinicalTrials.gov, identifier number NCT01913613.  
The EF inclusion criterion for HFpEF was consistent with prior studies (see for example28). 
However, subsequent to the start of the present study, new guidelines were published that 
defined HFpEF as EF≥50% and HFmrEF (heart failure with mid-range EF) as EF 40-49%.  As detailed 
below, the impact of EF range on the results were examined. 
Procedures 
All patients underwent RHC with assessment of cardiac output and central hemodynamics [right 
atrial pressure (RAP), pulmonary artery pressure (PAP), and PCWP] at rest and during supine 
ergometry at the following time points: baseline, 6 months, and optionally at 12 months after 
device implantation. Right heart catheterization was performed from either an antecubital or 
internal jugular vein with a 7F or 8F sheath.  Cardiac output was determined by thermodilution 
(at rest and during exercise) made at least in triplicate, and by Fick method at rest only; for the 
latter, oxygen consumption was assumed to be related to gender, age and heart rate according 
 9 
to previously validated equation and calculated at the hemodynamic core lab to ensure 
consistency of calculation.29 Following baseline resting hemodynamic measurements, 
measurements were taken 5 minutes after raising legs into the bicycle pedals and then during 
symptom-limited supine bicycle exercise starting at 20 watts (W) with 20W increments every 3 
min until the patient achieved maximum effort (defined by symptom limiting dyspnea or fatigue). 
Resting blood samples were collected from the pulmonary artery and superior and inferior vena 
cavae at baseline and at follow-up to measure oxygen saturation for assessment of left-to-right 
shunting as indexed by the pulmonary-to-systemic blood flow ratio (Qp:Qs). For calculation of 
Qp:Qs, we assumed that mixed venous oxygen saturation (SMV) was determined by 
SMV=(3·SSVC+SIVC)/4 where SSVC and SIVC were  blood oxygen saturations in the superior and 
inferior vena cavae, respectively.  Qp:Qs was then calculated as (SA-SMV) / (SA-SPA) where SA is the 
oxygen saturation of arterial blood SPA is oxygen saturation of pulmonary arterial blood. 
Device insertion was done within 45 days of screening evaluations. Implantation was performed 
percutaneously via the femoral vein on a separate occasion following hemodynamic 
qualification. Standard trans-septal puncture of the interatrial septum was performed using the 
operator's preferred technique, using fluoroscopy and transesophageal or intracardiac 
echocardiography, and the implant was inserted and positioned using an over-the-wire 
technique.  The IASD had an internal diameter of 8 mm.   
Outcomes 
The primary objective of this study was to assess exercise-induced hemodynamic changes 6 and 
12 months after device implantation. The hemodynamic endpoints measured were Qp:Qs, 
cardiac output, CVP, PAPs, PCWP, pulmonary vascular resistance (PVR) and aortic pressures. 
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Resting forward cardiac output was assessed by indirect Fick method using the estimated MVS 
(as quantified above). Hemodynamic tracings were analyzed at an independent core laboratory 
(PVLoops LLC, NY, USA).   
Analyses 
Hemodynamic tracings at each stage of exercise were printed, scanned and sent to a core lab for 
independent quantification of pressures at rest and at each stage of exercise.  Baseline and 
follow-up tests were read independently of each other in order to reduce bias.   
Normally distributed data are presented as mean (SD) and non-parametric data as median (IQR). 
We used a paired t test or Wilcoxon matched pair sign-rank test as appropriate to compare 
follow-up data versus baseline data. Linear regression analysis was applied to data at peak 
exercise and compared to baseline data by analysis of covariance (ANCOVA). The null hypothesis 
was rejected at p<0·05.  
Since the primary driver of flow through an IASD the pressure gradient between RA and LA, we 
examined the baseline PCWP-CVP difference and how it changed in response to the presence of 
the IASD.  Secondly, to understand the determinants of changes in the PCWP-CVP gradient, we 
examined plots of CVP vs PCWP to better elucidate the simultaneous impact of exercise on right 
and left-sided hemodynamics before and after IASD implant.  As in prior studies 30, 31 we divided 
the PCWP-CVP diagram into 5 quadrants (or zones) at rest and during exercise corresponding 
with different states of left- and right-sided congestion:  a normal zone with normal CVP and 
PCWPs; a zone of primary left-sided congestion with elevated PCWP and normal CVP; a zone of 
primary right-sided congestion with elevated CVP and normal PCWP; a zone with right- and left-
 11 
sided congestion with elevated CVP and PCWP; and a state of relative hypovolemia with both 
CVP and PCWP below the normal lower limits (detailed further below).  Based on recently 
published resting and exercise data,8, 32, 33 normal upper limits for CVP and PCWP at rest were set 
at 10 and 15 mmHg, respectively.  Normal upper limits for CVP and PCWP during exercise were 
set at 16 and 26 mmHg, respectively.  Finally, to assess the IASD operating characteristics, we 
explored hemodynamic factors that correlated with reductions of the PCWP-CVP gradient and 
reductions of PCWP at rest and during exercise. 
The data, analytic methods, and study materials will not be made available to other researchers 
for purposes of reproducing the results or replicating the procedure. 
 
Results 
Sixty-four patients underwent implantation of the IASD system. The demographics have been 
detailed previously 23, 24 and are summarized briefly in Table 1, in which demographics are also 
compared between patients with EF ≥50% and patients with EF < 50%.   There were no significant 
differences in clinical characteristics between these two subgroups (additional details below) 
except for a greater proportion of NYHA III patients in the EF<50% group (36% versus 72%).     
The group-averaged resting and peak exercise hemodynamic parameters at baseline and 6 
months post-IASD are summarized in Table 2.  Most of these data have been described 
previously.23  In brief, the key hemodynamic effects of IASD under resting conditions included a 
Qp:Qs (calculated from vena caval and pulmonary artery oxygen saturations) of 1.27±0.24 which 
resulted in increased resting cardiac output measured by thermodilution (indicative of flow 
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through the pulmonary circulation) and no change in resting cardiac output assessed by indirect 
Fick method (indicative of flow to the systemic circulation).  There was a small increase in resting 
CVP and a small decrease in resting PCWP.  In the majority of patients, the PCWP-CVP pressure 
difference decreased from baseline to 6 months following the IASD implant (Fig. 1A; note that in 
this and subsequent figures, the red symbols represent data from patients with EF≥50% while 
black symbols represent patients with EF<50%).  However, there was noticeable variability and 
the pressure gradient increased in some patients. 
Peak exercise tolerance increased 6 months following IASD from 42.5±18.3 at baseline to 
49.0±20.3 Watts at 6 months (p=0.002).  Work- and weight-normalized PCWP (PCWP/(Watts/Kg)) 
decreased significantly from 89.1±53.5 at baseline to 70.5±42.8 at 6 months post-IASD (p<0.001).  
As was the case at rest, the CVP at peak exercise increased while PCWP decreased.  Also, as was 
the case at rest, the PCWP-CVP pressure difference at peak exercise decreased 6 months 
following IASD implant, and there was significant variability (Fig. 1B). 
 
CVP-PCWP relationships at rest and exercise 
A further understanding of the impact of the IASD was revealed upon examining the relationship 
between CVP and PCWP in individual patients as illustrated in Fig. 2A and as summarized in Table 
3.  At baseline in the resting state, 37% of patients fell in the normal zone with PCWP and CVP 
within normal limits.  27% of patients were in the zone with ↑PCWP and normal CVP, and 34% 
in the ↑PCWP/↑CVP zone.  Six months following IASD, resting CVP and PCWP were more closely 
correlated to each other than at baseline (Fig. 2B); the percent of patients in the normal zone 
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was similar to baseline but there was a lower percentage of patients in the ↑PCWP quadrant 
and an increased percentage in the ↑PCWP/↑CVP quadrant (Fig. 2B, Table 3).   
During exercise at baseline, and accounting for exercise-appropriate normal upper limits, 8% of 
patients fell in the normal hemodynamic quadrant, 33% were in the ↑PCWP quadrant, and 59% 
were in the combined ↑PCWP/↑CVP quadrant (Fig. 2C, Table 3).  At 6-months following IASD 
implant, there was a greater percentage of patients in the normal quadrant, fewer in the ↑PCWP 
quadrant and similar numbers in the ↑CVP and ↑PCWP/↑CVP quadrants (Fig. 2D, Table 3).  
Linear regression analysis applied to the data at peak exercise showed that the PCWP-CVP 
relationship was shifted downward by ~4.7 mmHg at 6 months compared to baseline by ANCOVA 
which yielded the following regression coefficients:  PCWP = 20.9(1.7) - 4.7(1.1)·Treatment + 
0.76(0.08)·CVP (values in parenthases are standard errors of respective coefficients), where 
Treatment is a dummy variable that equals 0 for data obtained at baseline (prior to IASD) and 1 
for data obtained at 6 months following IASD (p<0.0001 for all coefficients).  In contrast, there 
was no impact of treatment on the slope of this relationship (p=0.65).   
Exercise-induced increases in PCWP were greater than concomitant increases in CVP; this is 
important since it suggests that the pressure gradient driving left-to-right flow increases during 
exercise and that the IASD-mediated reductions in PCWP will be greater during exercise.  There 
was a weak correlation between the increase of PCWP from rest to peak exercise (ΔPCWP) and 
the increase of CVP from rest to peak exercise (ΔCVP):  ΔPCWP = 13.7(1.8)+0.38(0.19)·ΔCVP  
(p=0.05, r2=0.065.  Six months following IASD these two parameters became more tightly 
correlated, presumably because of the communication between right and left atria:  ΔPCWP = 
11.0(1.0) + 0.45(0.09)·ΔCVP.   
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Hemodynamic correlations with IASD induced reductions in left-to-right pressure gradient 
The driving force for flow though the IASD is the pressure gradient between the LA and RA which 
is estimated by the difference between PCWP and CVP.  We therefore hypothesized that a 
greater baseline PCWP-CVP difference should be associated with greater shunting and a greater 
reduction of this gradient.  Notably, there were no statistically significant correlations between 
baseline values of hemodynamics at rest and changes in PCWP-CVP or changes in PCWP from 
data measured.  However, at peak exercise where PCWP-CVP differences were greater, there 
was an inverse relationship between baseline peak exercise PCWP-CVP pressure gradient and the 
change of this gradient from baseline to 6 months (Δ(PCWP-CVP), Fig. 3A):  Δ(PCWP-CVP) = 
10.0(1.9) – 0.89(0.11)·(PCWP-CVP)baseline  (r2=0.56, p<0.001).    Δ(PCWP-CVP) at peak exercise was 
also inversely correlated with baseline peak exercise PCWP (Fig. 3B):  Δ(PCWP-CVP) = 11.1(4.4) – 
0.46(0.13)·PCWPbaseline (r2=0.18, p<0.001).  Finally, Δ(PCWP-CVP) at peak exercise was inversely 
correlated to Qp:Qs measured 6 months following IASD implant (Fig. 3C): Δ(PCWP-CVP) = 
10.9(5.3) – 11.9(4.1)·Qp:Qs (p=0.005, r2 = 0.13). Thus, the greater the Qp:Qs, the greater the 
reduction of the PCWP-CVP pressure gradient. 
Importantly, the reduction of peak exercise PCWP at 6 months compared to baseline (ΔPCWP) 
was also correlated with the baseline peak exercise PCWP-CVP pressure gradient (Fig. 4): ΔPCWP 
= 7.54(2.5) - 0.60(0.14)·(PCWP-CVP) (p=0.001, r2=0.23).  Thus, the greater the driving pressure 
for shunt flow, the greater the reduction in peak exercise PCWP at 6 months. 
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Correlations between hemodynamics and exercise tolerance 
While neither baseline hemodynamic nor clinical characteristics correlated with changes in the 
amount of exercise performed, there was a significant correlation between the change in PCWP 
and the change in work- and weight-normalized peak PCWP [i.e., PCWP/(Watts/kg)]:    
Δ[PCWP/(Watts/kg]=-15.7(4.7) + 1.5(0.6)·ΔPCWP  (p=0.01).   
 
HFpEF versus HFmrEF 
As noted above, using an ejection fraction of ≥50% to define patients with HFpEF and <50% to 
define HFmrEF, there were no significant differences in baseline characteristics noted in Table 1.  
In addition, there were no differences in most of the baseline hemodynamic parameters 
(including CO, pulmonary vascular resistance and blood pressure or any resting hemodynamic 
parameters).  However, at peak exercise, compared with the HFpEF group, CVP (18.8±5.1 vs 
15.15.2, p=0.011) and PCWP (35.6±7.9 vs 31.3±6.3, p=0.029) were higher in the HFmrEF group.  
Nevertheless, the PCWP-CVP gradient did not differ between groups (16.9±6.8 mmHg for HFmrEF 
vs 16.6±7.1 mmHg for HFpEF, p=0.76).  At 6 months follow up, the PCWP-CVP difference 
decreased to 11.8±4.2 for HFmrEF and 11.0±6.5 for HFpEF (p=ns).  Regarding exercise tolerance, 
work- and weight-normalized PCWP values at baseline were 92.2±57.7 and 87.2±49.2 
(mmHg/Watt/kg) and these decreased to 73.8±44.7 and 69.0±39.0 in HFmrEF and HFpEF, 
respectively (p=ns for differences between HFpEF and HFmrEF groups).   Thus, while there were 
differences in baseline demographics and hemodynamics between patients segregated by EF, 
there were no differences in any of the hemodynamic and exercise responses to IASD.  Similarity 
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of responses to IASD in these two groups is appreciated visually in Figs. 1, 3 and 4, where data 
from patients of the two groups are shown with different colored symbols. 
 
Hemodynamics at 12-month follow-up  
Eighteen (18) patients underwent a protocol-specified optional repeat exercise hemodynamic 
evaluation at 12 months post IASD implantation. Results, summarized in Table 4, show that the 
impact on hemodynamics and exercise tolerance observed at 6 months were sustained at 12 
months.  However, even with the smaller number of patients the decrease in work- and weight-
normalized PCWP was statistically significant.   
 
Effect of changes of diuretic therapy 
It was previously reported that the median dose of orally administered furosemide at baseline 
was 40 mg per day (interquartile range 0-80).23  Although the median dose did not change over 
the 6-month follow up period so that the median change was 0 mg/day, diuretic doses were 
increased in 11 patients that resulted in an interquartile range from 0 to 15 mg/day.  When 
analyzed separately, patients in whom diuretic dose either remained the same or was decreased 
experienced an average 4 mmHg reduction in PCWP-CVP compared to an average 5 mmHg 
reduction in the patients whose diuretic dose was increased (p=0.55).  Thus, changes in diuretic 
dose did not impact the main findings described above. 
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Discussion 
This study examined the detailed effects of an interatrial shunt on resting and exercise 
hemodynamics in patients with a range of EFs spanning current definitions of HFpEF and HFmrEF.  
The analysis expanded the high level hemodynamic results presented in prior publications.23, 24   
Fundamentally, what an IASD can do is to reduce the difference between PCWP and CVP by 
allowing blood to flow from LA to RA; in principle, the reduced pressure gradient results from 
both a decrease of PCWP and an increase of CVP.  Accordingly, the focus of the present study 
was on understanding the hemodynamic determinants of IASD-mediated reductions of PCWP-
CVP gradient, CVP and PCWP.   
First, the PCWP-CVP gradient under resting conditions is relatively small.  Consequently, at 6 
months after IASD implantation, there was a relatively small, though statistically significant 
reduction of the resting PCWP-CVP gradient, an increase in CVP but no reduction of PCWP.  
However, resting values of CVP and PCWP were more closely correlated to each other after IASD 
implantation compared to baseline.  Importantly, baseline resting data did not correlate with 
hemodynamic effects of IASD at rest noted at 6 months.  At baseline (prior to IASD implantation) 
while elevations of CVP were quite significant during exercise, increases of PCWP were greater, 
so that the PCWP-CVP pressure difference increased dramatically during exercise. Consequently, 
the impact of the IASD on the PCWP-CVP gradient, PCWP and CVP were quantitatively larger 
during exercise than at rest.  As expected from theory17 the greater the PCWP-CVP difference, 
the greater the hemodynamic effects of IASD, on reducing both the PCWP-CVP gradient and on 
PCWP itself.  Also consistent with theory, the greater the Qp:Qs, the greater the reduction of the 
PCWP-CVP difference.   
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The impact of IASD on PCWP at peak exercise needs to be considered within the context the 
change in exercise performance.  Peak exercise tolerance is limited when PCWP rises with 
exercise beyond a threshold.  The IASD does not change that threshold level. Thus, a tight 
correlation between changes in PCWP and changes in exercise tolerance is not expected.  Instead, 
PCWP may approach a similar threshold at peak exercise following IASD.  This was indeed the 
case: there were both reductions of PCWP and increases in average Watts.  It is for this reason 
that we turn to the work- and weight-normalized PCWP (PCWP/(Watts/kg)) to assess the impact 
of IASD on exercise performance.  Lower values of this parameter have been associated with 
improved clinical outcomes in patient with HFpEF.7, 34 
While baseline characteristics and hemodynamics differed between patients with EF≥50% and 
those with EF<50%, the impact of the IASD on hemodynamics and exercise were indistinguishable 
between the two groups, a finding what is also supported by theory (i.e., that the IASD lowers 
PCWP by decompressing the overloaded left atrium, a pathophysiologic finding that is common 
in HFpEF and HFmrEF). 
Finally, all effects noted at 6 months were sustained through the 12 month follow up visit in the 
subset of patients who agreed to undergo optional repeat evaluation. 
The findings noted above have implications for the inclusion and exclusion criteria for selecting 
patients most likely to respond, at least hemodynamically, to IASD.  First, hemodynamic effects 
of IASD are not predicted by any parameter measured at rest; one must stress the 
cardiovascular system with exercise to identify hemodynamic derangements that identify 
favorable responders. This mirrors the diagnostic evaluation of HFpEF, where exercise 
assessment is necessary to identify hemodynamic perturbations that are often not apparent 
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from assessments at steady state where cardiovascular reserve is not stressed.4, 6, 8  Second, 
during exercise, patients with larger differences in PCWP and CVP are more likely to exhibit 
reductions of PCWP.  Finally, EF did not influence the hemodynamic effects over the range 
explored.  
Two other observations deserve further discussion.  First, as expected and reported previously, 
the presence of the shunt decreased PCWP at the expense of an increase in CVP both at rest and 
during exercise.  Since exercise is episodic, the increase of CVP during exercise may not be 
associated with any clinical effects.  CVP did not increase further between 6 and 12 months.  The 
consequences of a rise of CVP during rest (which was on average 1.6 mmHg) on end organ 
function (e.g., renal, hepatic, etc) should be followed in long term studies. Secondly, there was 
no impact of IASD presence on pulmonary artery pressures or PVR, despite the increased flow 
through the pulmonary arteries.  This suggests that there is no detrimental effect of the increased 
flow on the pulmonary vasculature and its ability to dilate in the face of increased flow through 
12 months of follow up. 
Several recent studies have highlighted the importance of understanding exercise hemodynamics 
in patients with HFpEF for guiding both the diagnosis and therapeutic developments.2, 4-6, 16, 19-21, 
35  Hemodynamics in many of these patients are relatively normal at rest (as in our study), but 
become rapidly abnormal upon initiation of mild exercise.4-6, 13, 16, 20, 21, 35  The mechanisms 
underlying exercise intolerance in these patients is debated,3, 13, 36 with many potential 
contributing factors. In addition to elevations of PCWP and limited capability to increase in stroke 
volume identified in many of the studies noted above, significant attention has also been placed 
on chronotropic incompetence.37  However, all of these factors are inherently interrelated.  Our 
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results obtained at baseline (prior to IASD implant) are in excellent quantitative agreement with 
all prior studies in that we observed marked increases in group averaged mean PCWP pressures, 
limited relative increases of peak exercise cardiac output to ~9 L/min 8, 35 (less than reported for 
age-matched normal subjects33) and low peak heart rates.   
As in our study, marked elevations of CVP have been observed during exercise in prior studies 
noted above but the implications have not been discussed in detail.38  This observation may hold 
additional clues as to the mechanisms of disease.  On an individual patient basis, exercise-induced 
changes in CVP were substantially greater than reported previously in age matched normal 
subjects.33  One recently proposed potential explanation for such CVP elevations is that patients 
with HFpEF and HFmrEF have impaired RV contractile reserve (i.e., inability to increase stroke 
volume) during exercise in addition to limited LV contractile reserve.8  However, a an argument 
against this hypothesis is the fact that both pulmonary and systemic arterial pressures rise 
substantially during exercise, and more so than in normal subjects, which would not be possible 
if contractility of either ventricle were impaired or limited.  For example, Santos observed 
increases in mean PAP to 41 mmHg in HFpEF patients (similar to our observed 45 mmHg) in 
comparison to a rise to only 30 mmHg in an age and gender matched control group.33  Similar 
observations were made by Borlaug et al who reported an increase of mean PAP to 48 mmHg.8  
The increase in pressure in the face of limited increases in stroke volume suggests abnormal 
ventricular-vascular coupling,8 rather than impaired contractile reserve. Another potential 
contributing mechanism may be exercise-induced, catecholamine-mediated splanchnic veno-
constriction which redistributes blood from the peripheral splanchnic to the central circulation.  
An older hypothesis regarding the role of veno-constriction in the generation of elevated PCWP 
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and CVP in heart failure (regardless of ejection fraction)39 has been recently revived, but not 
proven.14  In support of such concept, a recent study demonstrated that in response to a rapidly 
infused bolus of saline, PCWP, mean PAP and right atrial pressures increase more significantly in 
HFpEF patients than in controls.15  Although it has been suggested that such changes are 
indicative of intrinsic ventricular diastolic dysfunction, marked changes in filling pressure due to 
blood volume shifts can occur in the presence of normal intrinsic diastolic properties.40  This is 
relevant to the current data since increases in venous return occurring during exercise due to 
neurohormonal-mediated veno-constriction would be far greater than those associated with the 
experimental infusion of saline noted above.  Finally, most recently, it has been suggested that 
increased pericardial constraint may also contribute to this phenomenon, an effect that appears 
to be more pronounced among obese HFpEF patients.16, 40  Pericardial constraint is sure to 
exacerbate changes in filling pressures induced by increased venous return. 
Limitations 
The main limitation of the present study is the lack of a parallel control group.  Although the 
findings and conclusions of the present study are based on blinded assessment by a single core 
laboratory reader, non-IASD related changes in patient hemodynamic status over the follow up 
period cannot be excluded.  This may include changes in compliance with diet and medical 
therapies; however, as noted in our analysis, changes in diuretic therapy from baseline to 6 
months did not account for the observed hemodynamic predictors of IASD efficacy.  The 
magnitude of shunting was not assessed during exercise, which would have provided additional 
insight and is worth examining in future studies. 
Conclusions 
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In this heart failure patient population with EF>40%, both PCWP and CVP increased substantially 
during exercise, though the increases in PCWP were generally greater than those in CVP.  
Following IASD implantation with an average Qp:Qs of 1.27, PCWP and CVP became more 
strongly correlated with each other, a consequence of the hemodynamic communication with 
left to right flow between the atria.  The IASD significantly reduced the PCWP–CVP pressure 
gradient at rest and at peak exercise, a result of small increases in CVP and larger decreases in 
PCWP.  Work- and wight-normalized PCWP decreased significantly following the IASD.  There was 
variability in hemodynamic responses to IASD among patients but, overall, there was a direct 
relationship between the peak exercise PCWP-CVP pressure gradient (i.e. the driving force for 
left-to-right flow) and the reduction of peak exercise PCWP observed at 6 months.  These findings 
may have implications for selection of patients most likely to exhibit a chronic beneficial 
hemodynamic response to IASD implantation.  As expected, the greater the Qp:Qs, the greater 
the reduction in PCWP-CVP gradient.  Further investigations into the variability of Qp:Qs across 
the population is also important.  Findings were the same in the HFmrEF and HFpEF 
subpopulations.   
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Figure Legends 
Figure 1.  Difference between PCWP and CVP (an index of the estimated left-to-right atrial 
pressure gradient) at baseline and at 6 months, at rest (panel A) and at peak exercise (panel B).  
Most data points fall below the line of identity, indicating that the gradient is reduced at 6 
months compared to baseline.  Data from patients with ejection fraction ≥50 shown in red; data 
from patients with ejection fraction <50% shown in black. 
Figure 2.  Relationship between central venous pressure (CVP) and pulmonary capillary wedge 
pressure (PCWP) in individual patients at rest (panels A and C) and at peak exercise (panels B 
and D).  Justification of values used for upper limits of normal for CVP and PCWP, which define 
the “normal” quadrant at rest and during exercise is provided in the text.   Data are shown at 
baseline (panels A and B) and 6 months following InterAtrial Shunt Device (IASD, panels C and 
D).  The PCWP-CVP diagram is divided into 5 quadrants (or zones) at rest and during exercise 
corresponding with different states of left- and right-sided congestion:  a normal zone with 
normal CVP and PCWPs (green); a zone of primary left-sided congestion with elevated PCWP 
and normal CVP (pink); a zone of primary right-sided congestion with elevated CVP and normal 
PCWP (pink); a zone with right- and left-sided congestion with elevated CVP and PCWP (purple); 
and a state of relative hypovolemia with both CVP and PCWP below the normal lower limits 
(gray). 
Figure 3.  Baseline hemodynamic characteristics associated with an IASD-mediated reduction in 
the PCWP-CVP gradient at peak exercise include the baseline value of PCWP-CVP (panel A), 
PCWP itself (panel B) and the degree of shunting as quantified by the Qp:Qs (panel C). Data 
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from patients with ejection fraction ≥50 shown in red; data from patients with ejection fraction 
<50% shown in black. 
Figure 4.  The interatrial shunt-mediated reduction of pulmonary capillary wedge pressure 
(PCWP) at peak exercise was correlated with the baseline difference between PCWP and central 
venous pressure (CVP).  The baseline value of the PCWP-CVP gradient is the force that drives 
flow through the shunt and reduces both the gradient and the value of PCWP itself.  Data from 
patients with ejection fraction ≥50 shown in red; data from patients with ejection fraction <50% 
shown in black. 
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Table 1. Patient Characteristics 
 
    All Patients EF≥50% EF<50% p 
  n=64 n=23 n=41   
Variable Mean ± SD or % Mean ± SD or % Mean ± SD or %   
Age, years 69±8 69.7±7.7 69.4±8.8 0.90 
Gender, (M/F) 42/22 15/8 27/14 0.75 
NYHA Class (II/III) 27/73 9/14 9/32 0.01 
BMI, kg/m2 33±6 32±4 33±7 0.35 
Co-Morbidities     
 Diabetes (%) 34 35 34 0.95 
 Hypertension (%) 81 80 81 1.00 
 Atrial fibrillation (%) 61 50 68 0.17 
 CAD (%) 23 20 24 1.00 
MLWHFQ 49±20 46±18 51±20 0.32 
Six Minute Walk Test (m) 309±108 335±111 294±106 0.16 
Echocardiography (Core Lab)     
 LV end diastolic volume index (ml/m2) 68±13 62±16 71±13 0.01 
 LVEF (%) 47±7 55±4 43±5 <0.001 
 LV mass index (g/m2) 119±36 117±39 120±35 0.81 
 LA volume index (ml/m2) 34±17 30±9 38±20 0.18 
 RV diastolic volume index (ml/m2) 22±9 21±8 23±9 0.24 
 RA volume index (ml/m2) 35±17 31±16 37±18 0.24 
 E/A ratio 1.3±0.8 1.2±0.6 1.4±0.9 0.37 
 E/e’ ratio 13.9±5.9 13.7±4.3 14.0±6.7 0.88 
 TAPSE (mm) 20±4 21±3 20±5 0.37 
NT-Pro BNP (pg/mL, median, IQR) 377 (222-925) 287 (100, 460) 572 (257, 1208) 0.09 
 
Abbreviations:  M/F, male/female; NYHA, New York Heart Association functional class; BMI, 
body mass index; CAD, coronary artery disease; MLWHFQ, Minnesota Living with Heart Failure 
Questionnaire; LV, left ventricular; LA, left atrium; RV, right ventricle; RA, right atrium;  E/e’ 
ratio is the average of septal and lateral annuli motion; TAPSE, tricuspid annular plane systolic 
excursion. 
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Table 2. Average (±SD) resting and exercise hemodynamic results from the 64 patients who 
underwent evaluation at baseline and 6 months (superscripted numbers are p values versus 
respective baseline values). 
 
  At Rest Peak Exercise 
  Baseline 6 Months Baseline 6 Months 
Qp:Qs 1.06 ± 0.32 1.27 ± 0.24 <0.001 na ± na na ± na 
Peak Watts na ± na na ± na 42.5 ± 18.3 49.0 ± 20.3 0.002 
PA O2sat (%) 68.9 ± 6.0 75.0 ± 4.5 <0.001 46.9 ± 14.8 55.7 ± 12.5 <0.001 
HR (bpm) 68 ± 14 70 ± 12 95 ± 18 100 ± 20 0.019 
CO (TD, L/min)) 5.5 ± 1.6 6.7 ± 1.5 <0.001 8.7 ± 2.6 10.2 ± 2.7 <0.001 
CO (Fick, L/min) 4.6 ± 1.2 4.8 ± 1.3 na ± na na ± na 
CVP (mmHg) 9.0 ± 3.7 10.6 ± 5.1 0.027 17.5 ± 5.4 20.3 ± 7.9 0.041 
PAS (mmHg) 37 ± 11 38 ± 10 66 ± 14 67 ± 14 
PAD (mmHg) 17 ± 5 17 ± 5 33 ± 8 32 ± 8 
PAM (mmHg) 24 ± 7 24 ± 6 43 ± 9 43 ± 9 
PCWP (mmHg) 17.4 ± 5.2 16.5 ± 6.7 34.1 ± 7.6 31.6 ± 8.0 0.025 
PCWP-CVP (mmHg) 8.3 ± 4.1 6.1 ± 2.7 <0.001 16.8 ± 6.9 11.4 ± 5.5 <0.001 
PVR (mmHg/(L/min)) 1.3 ± 0.7 1.2 ± 0.5 1.2 ± 0.7 1.1 ± 0.6 
AoS (mmHg) 143 ± 23 143 ± 21 170 ± 28 180 ± 30 0.005 
AoD (mmHg) 72 ± 13 74 ± 10 88 ± 19 95 ± 23 0.02 
AoM (mmHg) 96 ± 14 97 ± 12 114 ± 20 122 ± 21 0.003 
PCWP/(Watts/Kg) na ± na na ± na 89.1 ± 53.5 70.5 ± 42.8 <0.001 
 
Abbreviations are as follows.  Qp:Qs, the ratio of flows through the pulmonary and systemic 
circulations; PA, pulmonary artery; HR, heart rate; CO, cardiac output; TD, thermodilution; CVP, 
central venous pressure; PAS, PAD and PAM, pulmonary artery systolic, diastolic and mean 
pressures, respectively; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular 
resistance ; AoS, AoD and AoM, aortic systolic, diastolic and mean pressures, respectively.  
Values without p values are not significantly different.
 31 
 
Table 3.  Percent distribution of patients over the 4 Filling Pressure 
Quadrants at baseline and 6 months, at rest and at peak exercise. 
 
    Filling Pressure Quadrant* 
  Normal Elevated PCWP Elevated CVP 
Elevated CVP and 
PCWP 
Resting 
Baseline 37 27 2 34 
6 Months 37 14 3 46 
Peak 
Exercise  
Baseline 8 33 0 59 
6 Months 17 22 3 58 
*All numbers are percentages
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Table 4. Resting and exercise hemodynamic results in 18 patients who underwent protocol-specified evaluations at baseline, 6 
month and protocol-specified optional evaluation at 12 months (superscripted numbers are p values versus baseline) 
 
n=18 At Rest Peak Exercise 
  Baseline 6 Months 12 Months Baseline 6 Months 12 Months 
Qp:Qs 1.09 ± 0.39 1.21 ± 0.2 1.30 ± 0.25                   
Ex Duration (min)                   8.2 ± 3.4 9.7 ± 3.18 0.03 10.4 ± 4.24 0.05 
Peak Watts                   47.8 ± 18.3 57.8 ± 18.0 0.02 55.0 ± 15.5 0.01 
PA O2sat (%) 69 ± 7.4 75.0 ± 3.6 0.003 74.4 ± 2.78 0.02 44.6 ± 15.2 51.7 ± 11.43 0.01 56.7 ± 17.9 0.02 
CO (TD, L/min) 5.2 ± 1.2 6.3 ± 1.4 <0.001 6.8 ± 1.8 0.003 8.7 ± 2.4 10.1 ± 2.3 0.01 11.4 ± 2.9 0.002 
CO (Fick L/min)) 4.8 ± 1.4 5.1 ± 1.3 5.6 ± 1.6 0.05                   
CVP (mmHg) 8.4 ± 3.5 10.6 ± 5.9 10.4 ± 3.5 0.02 17.7 ± 6.2 20.9 ± 8.8 21.4 ± 8.3 0.02 
PAM (mmHg) 25 ± 8 23 ± 7 26 ± 8 45 ± 11 45 ± 11 45 ± 13 
PCWP (mmHg) 18.8 ± 6.1 16.4 ± 7.5 17.4 ± 6.0 36.3 ± 8.5 33.4 ± 9.1 33.2 ± 10.4 
PCWP-CVP 10.4 ± 4.7 5.8 ± 2.4 7.0 ± 3.6 19.3 ± 7.1 12.5 ± 4.8 11.8 ± 6.4 
PVR 
((mmHg/L/min) 1.3 ± 0.7 1.2 ± 0.6 1.3 ± 0.5 1.1 ± 0.9 1.1 ± 0.5 1.2 ± 0.7 
AoS (mmHg) 153 ± 21.8 147 ± 21.06 146.6 ± 18.89 165 ± 36 166 ± 37.2 178 ± 25.9 
AoD (mmHg) 75 ± 12 79 ± 8 79 ± 9.2 82 ± 22 89 ± 13.9 91 ± 14.4 
AoM (mmHg) 101 ± 13 101 ± 10 101 ± 10.2 110 ± 25 114 ± 13.2 120 ± 12.9 
PCWP/(Watts/Kg)                   84.29 ± 49.47 59.7 ± 34.61 0.02 62.2 ± 34.43 <0.001 
 
 




